Time To Strike On Regenerative Medicine/Stem Cell Companies?
As the hype that accompanied the revelation of regenerative medicine recedes, biotechs that survived the transition from science experiment to market-focused company have now settled into the same realities that face the rest of the industry in terms of making the case for reimbursement and preparing for regulatory scrutiny, not to mention the exit question.
You may also be interested in...
The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.
Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.
The evening before Advanced BioHealing Inc. was set to debut on the New York Stock Exchange on May 18, it announced that Shire PLC has agreed to buy it for $750 million.